Merck & Co., Inc. announced a voluntary withdrawal of Vioxx (rofecoxib) from the U.S. market due to safety concerns. Vioxx is a prescription COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by FDA in May 1999 for the relief of the signs and symptoms of osteoarthritis, for the management of acute pain in adults, and for the treatment of menstrual symptoms. It is also approved for the relief of the signs and symptoms of rheumatoid arthritis in adults and children.
The Federal Drug Administration was informed by Merck & Co., Inc. on September 27, 2004, that the Data Safety Monitoring Board for an ongoing long-term study of Vioxx (APPROVe) had recommended that the study be stopped early for safety reasons. The study showed an increased risk of cardiovascular events (including heart attack and stroke) in patients on Vioxx, particularly those who had been taking the drug for longer than 18 months. Based on this new safety information, Merck and FDA was informed that Merck was voluntarily withdrawing Vioxx from the market place. The risk is that an individual patient taking Vioxx will suffer a heart attack or stroke.
Patients taking Vioxx should contact their primary care physician to discuss other treatment options.
Users of Vioxx who have suffered a heart attack, stroke, or other cardiovascular event may be entitled to monetary compensation. If you or someone you know have suffered a heart attack or stroke while taking Vioxx, please feel free to contact us at (518) 458-1220. As always, your consultation with us will be free of charge.
Get help immediately.